Therapeutic drug monitoring and pharmacogenetics to tune imatinib exposure in gastrointestinal stromal tumor patients: hurdles and perspectives for clinical implementation.

Clicks: 122
ID: 280525
2023
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Tweetable abstract Present evidence supports the use of intensified pharmacologic monitoring of #imatinib including #TherapeuticDrugMonitoring and #PGx to improve outcomes in patients with GI stromal tumor. Future studies need to address emerging questions to facilitate implementation in clinics.
Reference Key
gagno2023therapeuticpharmacogenomics Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Gagno, Sara;Fratte, Chiara Dalle;Posocco, Bianca;Buonadonna, Angela;Fumagalli, Arianna;Guardascione, Michela;Toffoli, Giuseppe;Cecchin, Erika;
Journal Pharmacogenomics
Year 2023
DOI
10.2217/pgs-2023-0198
URL
Keywords
therapeutic drug monitoring imatinib pharmacogenetics gastrointestinal stromal tumor ctrough precision dosing

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.